Abstract
Laser panretinal photocoagulation (PRP) reduces visual loss in proliferative diabetic retinopathy but decreases peripheral retinal function. The Driver and Vehicle Licensing Centre (DVLC) states that when a patient volunteers that he or she has had photocoagulation, a questionnaire will then be sent to the patient's diabetic physician who can refer the patient for formal field testing. Of 30 patients who had PRP, 15 failed DVLC visual field regulations using the Esterman binocular field test on the Humphrey field analyser. The failures were more likely to have had treatment with a xenon laser, but there was no difference between the groups as regards age, number of burns or whether an argon or diode laser was used. The patients who failed were more likely to be hypertensive (p = 0.04). Two patients with unilateral PRP could not meet the driving regulations because of other field defects. Diabetes itself causes field defects, and therefore even with small amounts of laser, formal field testing may be necessary.
Similar content being viewed by others
Article PDF
References
The Diabetic Retinopathy Research Group: Photocoagulation treatment of proliferative diabetic retinoapathy: the second report of diabetic retinopathy study findings. Ophthalmology 1978, 85: 82–106.
Sieberth V, Alexandrides E, Feng W : Function of the diabetic retina after panretinal argon laser coagulation. Graefes Arch Clin Exp Ophthalmol 1987, 225: 385–90.
Zaluski S, Marcil G, Lamer L, Lambert J : Study of the visual field using automated static perimetry following PRP in the diabetic. J Fr Ophtalmol 1986, 9: 395–401.
Munton G : Form CLE 1060. DVLC Drivers Medical Branch, September 1988.
Kulze JC, Stewart WC, Sutherland SE : Factors associated with a learning effect in glaucoma patients using automated perimetry. Acta Ophthalmol (Copenh) 1990, 68: 681–6.
Sleight P : Oxford Textbook of Medicine. Oxford University Press, 1987: 360–81.
Balles M, Puliafito C, D'Amico D, Jacobson J, Bamgruber R : Semiconductor diode laser photocoagulation in retinal vascular disease. Ophthalmology 1990, 97: 1553–60.
McHugh JDA, Marshall J, ffytche TJ, Hamilton AM, Raven A, Keeler CR : Initial clinical experience using a diode laser in the treatment of retinal vascular disease. Eye 1989, 3: 516–27.
Tso M, Wallow I, Elgin S : Experimental photocoagulation of the human retina. Arch Ophthalmol 1977, 85: 1035–40.
Seiberth V, Alexandridis E : Function of the diabetic retina after panretinal argon laser photocoagulation: influence of the intensity of the coagulation spots. Ophthalmologica 1991, 202: 10–7.
Trick GL, Trick LR, Kilo C : Visual field defects in patients with insulin-dependent and non-insulin-dependent diabetes. Ophthalmology 1990, 97: 475–82.
Parving HH : Impact of blood pressure and antihypertensive treatment on incipient and overt nephropathy, retinopathy and endothelial permeability in diabetes mellitus. Diabetes Care 1991, 14: 260–9.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Buckley, S., Jenkins, L. & Benjamin, L. Fields, DVLC and panretinal photocoagulation. Eye 6, 623–625 (1992). https://doi.org/10.1038/eye.1992.134
Issue Date:
DOI: https://doi.org/10.1038/eye.1992.134
Keywords
This article is cited by
-
The effects of visual-field loss from panretinal photocoagulation of proliferative diabetic retinopathy on performance in a driving simulator
Eye (2023)
-
Therapie der proliferativen diabetischen Retinopathie
Der Diabetologe (2018)
-
Effects of conventional argon panretinal laser photocoagulation on retinal nerve fibre layer and driving visual fields in diabetic retinopathy
Eye (2010)
-
Passing the DVLA field regulations following bilateral macular photocoagulation in diabetics
Eye (2000)
-
Altering the pattern of panretinal photocoagulation: Could the visual field for driving be preserved?
Eye (1999)